Marina Biotech Inc. is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics. The company’s innovative therapeutics utilize multiple mechanisms of action, including RNA interference and messenger RNA translational blocking.
The company reported today that China’s State Intellectual Property Office has issued a Notification of Granting Patent Rights for PRC 200680047851. This patent covers pharmaceutical formulations for intranasal delivery of insulin, and uses of the formulation to treat diseases associated with inappropriate insulin levels.
The president of CEO of Marina Biotech, J. Michael French, said, “We believe that the intranasal assets from our predecessor company, Nastech Pharmaceutical, have considerable value. Our intranasal insulin program has the potential to serve patients with diabetes, and holds additional promise in the treatment of CNS (central nervous system) diseases such as Alzheimer’s.”
Combined with the current patent protection in Europe, this patent grant in China further expands and strengthens the company’s insulin patent portfolio. For additional information about Marina Biotech and its products, please visit the company’s website at www.marinabio.com
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment